Aquestive Therapeutics, Inc.
AQST · XNASCIK 1398733fmd_1AZVW31WDV7NM915G5GVQTC10RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
Loading
Latest annual · FY2025
Millions- Total revenues
- 45
- Gross profit
- 26
- Operating income
- (71)
- Net income
- (84)
Latest quarter · Q3 FY2026
Millions- Free cash flow
- (8)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -2.2%
- Revenue, 5 yearsFY2020 to FY2025
- -0.6%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Aquestive Therapeutics, Inc. (AQST) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $44.5 million | $57.6 million | -22.6% | 10-K 2026-03-04 · proof |
| Gross profit | $26 million | $39.7 million | -34.5% | 10-K 2026-03-04 · proof |
| Operating income | -$71.1 million | -$30.8 million | 10-K 2026-03-04 · proof | |
| Net income | -$83.8 million | -$44.1 million | 10-K 2026-03-04 · proof | |
| Total assets | $160.4 million | $101.4 million | +58.2% | 10-K 2026-03-04 · proof |
| Total liabilities | $194.1 million | $161.6 million | +20.1% | 10-K 2026-03-04 · proof |
| Cash and cash equivalents | $121.2 million | $71.5 million | +69.4% | 10-K 2026-03-04 · proof |
| Total debt | $37.5 million | 10-Q 2026-08-11 · proof |
- What was Aquestive Therapeutics, Inc. (AQST)'s revenue in fiscal 2025?
- Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $57.6 million the year before (-22.6%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Aquestive Therapeutics, Inc. (AQST)'s gross profit in fiscal 2025?
- Aquestive Therapeutics, Inc. (AQST) reported gross profit of $26 million for fiscal 2025 (the year ended Dec 31, 2025), against $39.7 million the year before (-34.5%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Aquestive Therapeutics, Inc. (AQST)'s operating income in fiscal 2025?
- Aquestive Therapeutics, Inc. (AQST) reported operating income of -$71.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$30.8 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Aquestive Therapeutics, Inc. (AQST)'s net income in fiscal 2025?
- Aquestive Therapeutics, Inc. (AQST) reported net income of -$83.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$44.1 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What are Aquestive Therapeutics, Inc. (AQST)'s total assets?
- As of Dec 31, 2025, Aquestive Therapeutics, Inc. (AQST) reported total assets of $160.4 million, against $101.4 million a year earlier (+58.2%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What are Aquestive Therapeutics, Inc. (AQST)'s total liabilities?
- As of Dec 31, 2025, Aquestive Therapeutics, Inc. (AQST) reported total liabilities of $194.1 million, against $161.6 million a year earlier (+20.1%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What are Aquestive Therapeutics, Inc. (AQST)'s cash and cash equivalents?
- As of Dec 31, 2025, Aquestive Therapeutics, Inc. (AQST) reported cash and cash equivalents of $121.2 million, against $71.5 million a year earlier (+69.4%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What is Aquestive Therapeutics, Inc. (AQST)'s total debt?
- As of Dec 31, 2025, Aquestive Therapeutics, Inc. (AQST) reported total debt of $37.5 million. Source: the 10-Q filed with the SEC on Aug 11, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:AQST&period_type=annual&limit=5"Information only, not investment advice.